The dog-loving world went into meltdown recently, with the announcement of a brand new drug to help increase the life expectancy of large-breed dogs.
The company behind it, Loyal is on the path to getting conditional approval from the US FDA for the drug and has also just kicked off a new study for a pill that’d see our smaller four-legged friends live longer, too. So how soon can we expect to see these treatments available? And what are the ethical issues surrounding such a pill?
On today’s episode of The Briefing, we chat with Brennen McKenzie, the Director of Veterinary Medicine at Loyal.
Headlines:
Labor is going to have to re-work its right to disconnect legislation
Global warming exceeds 1.5c level
Live export update
Paris medals to have Eiffel Tower in them
Follow The Briefing:
Instagram: @thebriefingpodcast
Facebook: TheBriefingNewsAU
Twitter: @TheBriefingAU
See omnystudio.com/listener for privacy information.
